​

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RARE Stock Forecast

Ultragenyx Pharmaceutical (RARE) stock forecast, based on 33 Wall Street analysts, predicts a 12-month average price target of $48.36, with a high of $67.00 and a low of $26.00. This represents a 112.20% increase from the last price of $22.79.

$20 $30 $40 $50 $60 $70 High: $67 Avg: $48.36 Low: $26 Last Closed Price: $22.79

RARE Stock Rating

Ultragenyx Pharmaceutical stock's rating consensus is Buy, based on 33 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 27 Buy (81.82%), 5 Hold (15.15%), 1 Sell (3.03%), and 0 Strong Sell (0.00%).

Buy
Total 33 1 5 27 Strong Sell Sell Hold Buy Strong Buy

RARE Price Target Upside V Benchmarks

TypeNameUpside
StockUltragenyx Pharmaceutical112.20%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-519
Avg Price Target-$47.80$48.79
Last Closing Price$22.79$22.79$22.79
Upside/Downside-109.74%114.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 265122--19
May, 265132--20
Apr, 265132--20
Mar, 265141--20
Feb, 265151--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 08, 2026Wedbush$26.00$26.17-0.65%14.09%
May 08, 2026Guggenheim$43.00$26.1364.56%88.68%
Apr 29, 2026Eliana MerleBarclays$43.00$24.5375.30%88.68%
Apr 16, 2026Morgan Stanley$67.00$25.02167.79%193.99%
Mar 12, 2026Joseph SchwartzLeerink Partners$60.00$21.36180.90%163.27%
Feb 18, 2026Gavin Clark-GartnerEvercore ISI$34.00$20.1468.82%49.19%
Feb 17, 2026Evercore ISI$37.00$20.5280.31%62.35%
Feb 17, 2026Raghuram SelvarajuH.C. Wainwright$50.00$20.52143.66%119.39%
Feb 13, 2026Goldman Sachs$61.00$21.32186.12%167.66%
Feb 13, 2026Robert W. Baird$40.00$21.2788.06%75.52%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 21, 2026Cantor FitzgeraldOverweightOverweighthold
Apr 29, 2026BarclaysOverweightOverweighthold
Apr 16, 2026Morgan StanleyOutperformOutperformhold
Mar 24, 2026Goldman SachsBuyNeutraldowngrade
Mar 12, 2026Bank of America SecuritiesBuyBuyhold
Mar 12, 2026Leerink PartnersOutperformOutperformhold
Feb 18, 2026Evercore ISIOutperformOutperformhold
Feb 17, 2026H.C. WainwrightBuyBuyhold
Jan 27, 2026BarclaysOverweightOverweighthold
Jan 02, 2026Bank of America SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-9 $-3 $3 $9 $15 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.70$-10.12$-8.25$-6.29$-5.83---
Avg Forecast$-6.25$-9.92$-8.37$-6.21$-5.11$-3.40$-0.17$4.13
High Forecast$-5.97$-8.61$-7.92$-5.92$-3.82$-0.80$10.08$4.20
Low Forecast$-7.03$-10.84$-9.13$-6.64$-6.32$-5.82$-9.87$4.02
Surprise %7.20%2.02%-1.43%1.29%14.09%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$351.41M$363.33M$434.25M$560.23M$673.00M---
Avg Forecast$351.78M$361.74M$428.63M$546.66M$645.00M$858.55M$1.22B$1.83B
High Forecast$385.16M$387.56M$432.53M$556.16M$647.02M$870.71M$1.28B$1.85B
Low Forecast$339.42M$325.03M$423.24M$536.88M$643.00M$846.38M$1.17B$1.79B
Surprise %-0.11%0.44%1.31%2.48%4.34%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-454.02M$-707.42M$-606.64M$-569.18M$-575.00M---
Avg Forecast$-396.60M$-413.87M$-606.64M$-461.94M$-372.86M$-338.45M$13.07M$303.83M
High Forecast$-317.28M$-331.09M$-485.31M$-435.51M$-281.15M$-58.80M$741.13M$309.09M
Low Forecast$-475.92M$-496.64M$-727.97M$-488.37M$-464.57M$-427.75M$-725.65M$295.72M
Surprise %14.48%70.93%-23.22%54.21%---

RARE Forecast FAQ

Is Ultragenyx Pharmaceutical stock a buy?

Ultragenyx Pharmaceutical stock has a consensus rating of Buy, based on 33 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 27 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Ultragenyx Pharmaceutical is a favorable investment for most analysts.

What is Ultragenyx Pharmaceutical's price target?

Ultragenyx Pharmaceutical's price target, set by 33 Wall Street analysts, averages $48.36 over the next 12 months. The price target range spans from $26 at the low end to $67 at the high end, suggesting a potential 112.20% change from the previous closing price of $22.79.

How does Ultragenyx Pharmaceutical stock forecast compare to its benchmarks?

Ultragenyx Pharmaceutical's stock forecast shows a 112.20% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ultragenyx Pharmaceutical over the past three months?

  • June 2026: 26.32% Strong Buy, 63.16% Buy, 10.53% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 25.00% Strong Buy, 65.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 25.00% Strong Buy, 65.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Ultragenyx Pharmaceutical’s EPS forecast?

Ultragenyx Pharmaceutical's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.4, marking a -41.68% decrease from the reported $-5.83 in 2025. Estimates for the following years are $-0.17 in 2027, and $4.13 in 2028.

What is Ultragenyx Pharmaceutical’s revenue forecast?

Ultragenyx Pharmaceutical's average annual revenue forecast for its fiscal year ending in December 2026 is $858.55M, reflecting a 27.57% increase from the reported $673M in 2025. The forecast for 2027 is $1.22B, and $1.83B for 2028.

What is Ultragenyx Pharmaceutical’s net income forecast?

Ultragenyx Pharmaceutical's net income forecast for the fiscal year ending in December 2026 stands at $-338M, representing a -41.14% decrease from the reported $-575M in 2025. Projections indicate $13.07M in 2027, and $303.83M in 2028.